The Union Ministry of Health and Family Welfare has proposed amending Rule 31 of the Drugs Rules, 1945, to change the mandatory residual shelf-life for imported drugs from "more than 60 percent" to a fixed "12 months". Published via Gazette Notification G.S.R. 505 (E) on June 22, 2026, the move aims to promote the Ease of Doing Business, optimize pharmaceutical supply chains, and reduce drug wastage. However, sensitive items like biological products and radiopharmaceuticals will remain subject to the old 60 percent rule to protect public health.
On June 26, 2026, the Press Information Bureau announced that the Union Health Ministry issued a draft notification (G.S.R. 505 (E) dated June 22, 2026) to amend Rule 31 of the Drugs Rules, 1945. The amendment alters the residual shelf-life mandate for imported drugs from a proportional metric (more than 60% remaining) to a fixed time-based metric (minimum 12 months remaining). Public comments have been invited to finalize this modification.
The Gazette notification was officially published on June 22, 2026, with the public announcement coming from New Delhi on June 26, 2026. The rule will universally apply to all designated drug import ports across India once finalized.
This regulatory tweak directly impacts the Ease of Doing Business (UPSC GS Paper 3 — Economy) by easing rigid import bottlenecks. Economically, it minimizes avoidable wastage of highly specialized, often expensive, imported medicines that previously failed the 60% rule. Socially, it guarantees uninterrupted availability of life-saving drugs for patients, as 12 months provides a sufficient window for domestic distribution and consumption.
📌 [BACKGROUND — verify independently] The regulation of pharmaceutical imports in India has steadily evolved to balance domestic safety with global trade.
📌 [BACKGROUND — verify independently]
India is often termed the "pharmacy of the world" due to its massive generic drug export volume. However, India still heavily relies on imports for patented drugs, oncology medicines, and high-end medical devices. ⚠️ [SOURCE NEEDED] Globally, regulatory bodies like the US FDA focus on rigorous stability testing and risk-based expiration dating rather than applying blanket percentage-based shelf-life rules at import borders.
Once the notification period concludes and the rule is codified, foreign pharmaceutical companies will likely adjust their inventory and shipping models for the Indian market. In the short term, this will clear backlogs of viable medicines stuck at ports. Over the next few years, the reduction in drug wastage could marginally lower the retail cost of highly specialized imported therapies.
Core Concept: Drugs and Cosmetics Act, 1940 (Import Regulations)
Q1. Under the proposed amendment to the Drugs Rules, 1945, what is the new minimum residual shelf-life required for general imported drugs? [Easy]
A) 6 months
B) 12 months
C) 24 months
D) More than 60 percent
Answer: B
Explanation: The draft notification proposes revising the requirement to a minimum residual shelf life of 12 months at the time of import.
Q2. Which Ministry published the draft notification regarding the residual shelf-life of imported drugs? [Easy]
A) Ministry of Commerce and Industry
B) Ministry of Chemicals and Fertilizers
C) Ministry of Health and Family Welfare
D) Ministry of Science and Technology
Answer: C
Explanation: The Union Ministry of Health and Family Welfare issued the draft Gazette Notification G.S.R. 505 (E).
Q3. Which specific rule of the Drugs Rules, 1945 is being amended to rationalise shelf-life requirements? [Moderate]
A) Rule 21
B) Rule 31
C) Rule 45
D) Rule 60
Answer: B
Explanation: The government has proposed amendments to Rule 31 of the Drugs Rules, 1945.
Q4. Under the proposed amendment, which of the following categories of products will STILL require a residual shelf life of more than 60 percent? [Moderate]
A) Generic paracetamol and antibiotics
B) Medical devices and surgical equipment
C) Biological products and radiopharmaceuticals
D) Active Pharmaceutical Ingredients (APIs)
Answer: C
Explanation: Due to their specialized nature, biological products and radiopharmaceuticals are exempted and still require >60% residual shelf life.
Q5. What is the primary objective of changing the residual shelf-life from a percentage to a fixed 12-month period? [Moderate]
A) To increase customs revenue from imported medical devices
B) To promote Ease of Doing Business and reduce drug wastage
C) To ban the import of all foreign-made generic medicines
D) To alter the safety and efficacy testing standards of the drugs
Answer: B
Explanation: The proposal aims to optimize supply management, reduce avoidable wastage, and facilitate Ease of Doing Business.
Q6. If an imported drug originally has a total shelf life of 18 months, what was the minimum shelf life required upon arrival in India under the OLD rule (prior to this amendment)? [Tricky]
A) 6 months
B) 9 months
C) More than 10.8 months
D) 12 months
Answer: C
Explanation: The old rule required more than 60% of the shelf life remaining. 60% of 18 months is 10.8 months.
Q7. Consider the impact of the proposed draft notification G.S.R. 505 (E). Which of the following regulatory aspects under the Drugs and Cosmetics Act, 1940 will be directly relaxed? [Tricky]
A) Phase-3 clinical trial requirements for foreign drugs
B) Quality testing parameters at the port of entry
C) Efficacy documentation required for customs clearance
D) None of the above
Answer: D
Explanation: The Ministry explicitly clarified that the proposal does NOT alter any other regulatory requirements relating to quality, safety, or efficacy.
Q8. Why does the government maintain stricter shelf-life rules for radiopharmaceuticals compared to standard imported tablets? [Tricky]
A) They are manufactured exclusively by hostile nations.
B) They involve unstable radioactive isotopes that degrade quickly, raising public health concerns.
C) They are exempt from customs duty and require strict trade monitoring.
D) The Drugs and Cosmetics Act of 1940 does not legally recognize them as drugs.
Answer: B
Explanation: They retain the >60% requirement in view of their "specialised nature and public health considerations," as radiopharmaceuticals degrade rapidly.
PYQ 1:
With reference to pharmaceutical regulations in India, the Drugs Rules, 1945, which govern the import, manufacture, and distribution of medicines, were framed under which of the following legislations?
A) Pharmacy Act, 1948
B) Drugs and Cosmetics Act, 1940
C) Epidemic Diseases Act, 1897
D) Essential Commodities Act, 1955
Answer: B
Explanation: The Drugs Rules, 1945 were framed under the authority granted by the parent legislation, the Drugs and Cosmetics Act, 1940.
PYQ 2:
Consider the following statements regarding the recent draft amendment to the Drugs Rules, 1945:
1. The minimum residual shelf life for all imported medicines has been fixed at 12 months.
2. The amendment alters the quality and efficacy testing standards for imported drugs to promote Ease of Doing Business.
3. Biological products will continue to require a residual shelf life of more than 60 percent at the time of import.
Which of the above statements is/are correct?
A) 1 and 2 only
B) 3 only
C) 1 and 3 only
D) 1, 2, and 3
Answer: B
Explanation: Statement 1 is incorrect because not all medicines are fixed at 12 months (biologicals are exempt). Statement 2 is incorrect as the amendment strictly does not alter quality or efficacy standards. Statement 3 is correct.
PYQ 3:
Assertion (A): The Ministry of Health and Family Welfare has proposed to maintain the residual shelf-life requirement of more than 60 percent for imported radiopharmaceuticals, despite relaxing rules for other drugs.
Reason (R): Radiopharmaceuticals possess a specialized nature and pose specific public health considerations that necessitate longer residual usability upon import.
Select the correct code:
A) Both A and R are true and R is the correct explanation of A.
B) Both A and R are true but R is not the correct explanation of A.
C) A is true but R is false.
D) A is false but R is true.
Answer: A
Explanation: The government explicitly retained the 60% rule for radiopharmaceuticals precisely due to their specialized nature and the associated public health considerations, making R the correct explanation for A.
Question 1 (150 words): Discuss the significance of rationalising the residual shelf-life of imported drugs on India's healthcare supply chain.
Rationalising the residual shelf-life of imported drugs from a rigid 60 percent to a fixed 12 months is a vital reform for India's healthcare supply chain. Primarily, it addresses severe logistical bottlenecks. Previously, critical imported medicines were often rejected at customs if slight shipping delays pushed them just below the 60 percent threshold, leading to massive avoidable wastage.
Economically, this amendment optimizes supply management for importers and reduces inventory losses, which ultimately helps control the end-cost of specialized therapies for Indian patients. Administratively, the notification issued in June 2026 exemplifies the government’s push for 'Ease of Doing Business' within the highly regulated pharmaceutical sector.
By simultaneously retaining the stricter 60 percent rule for sensitive items like biological products and radiopharmaceuticals, the policy ensures a balanced approach. Moving forward, this rationalisation will guarantee a smoother, uninterrupted flow of essential, life-saving foreign medicines without compromising patient safety or drug efficacy.
Question 2 (250 words): "Reforming pharmaceutical import regulations requires balancing the Ease of Doing Business with stringent patient safety." Analyze this statement in the context of the recent amendments to the Drugs Rules, 1945.
Pharmaceutical regulation inherently demands a tightrope walk between facilitating swift market access for businesses and ensuring absolute safety for patients. The recent draft notification by the Ministry of Health and Family Welfare, which amends Rule 31 of the Drugs Rules, 1945, serves as a prime example of achieving this critical balance.
Historically, India mandated that imported drugs must have more than 60 percent of their original shelf life remaining upon entry. While well-intentioned to prevent the dumping of near-expiry drugs, this proportional metric became an administrative hurdle. For a drug with a five-year shelf life, a requirement of three remaining years was overly restrictive, leading to the destruction of perfectly viable, expensive medicines delayed in global transit. By modifying this to a flat 12-month residual shelf-life requirement, the government has directly promoted the 'Ease of Doing Business'. This optimized supply management reduces financial losses for importers and ensures Indian patients do not face shortages of vital foreign medicines.
Crucially, the reform does not compromise patient safety. A 12-month window provides adequate time for domestic distribution and consumption before expiration. Furthermore, the Ministry astutely exempted highly sensitive biological products and radiopharmaceuticals, maintaining their 60 percent threshold due to their rapid degradation profiles. Most importantly, the amendment strictly pertains to logistical shelf-life at import, leaving all safety, quality, and efficacy checks under the Drugs and Cosmetics Act unaltered.
To sustain this balance, future policies should integrate digital tracking systems like API QR codes to monitor post-import distribution, ensuring that business facilitation continually aligns with public health mandates.